ECSP19083621A - Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue - Google Patents
Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengueInfo
- Publication number
- ECSP19083621A ECSP19083621A ECSENADI201983621A ECDI201983621A ECSP19083621A EC SP19083621 A ECSP19083621 A EC SP19083621A EC SENADI201983621 A ECSENADI201983621 A EC SENADI201983621A EC DI201983621 A ECDI201983621 A EC DI201983621A EC SP19083621 A ECSP19083621 A EC SP19083621A
- Authority
- EC
- Ecuador
- Prior art keywords
- dengue viral
- inhibitors
- compounds
- indoline derivatives
- viral replication
- Prior art date
Links
- 208000001490 Dengue Diseases 0.000 title abstract 4
- 206010012310 Dengue fever Diseases 0.000 title abstract 4
- 208000025729 dengue disease Diseases 0.000 title abstract 4
- 150000002476 indolines Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000029812 viral genome replication Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000036142 Viral infection Diseases 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 238000002360 preparation method Methods 0.000 abstract 3
- 230000009385 viral infection Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 125000003387 indolinyl group Chemical class N1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención se refiere a derivados de indolina sustituidos, a métodos para prevenir o tratar infecciones virales por dengue mediante el uso de dichos compuestos y también se refiere a dichos compuestos para su uso como medicamento, más preferentemente, para su uso como medicamento para tratar o prevenir infecciones virales por dengue. La presente invención se refiere además a composiciones farmacéuticas o preparados combinados de los compuestos, a las composiciones o preparados para su uso como un medicamento, más preferentemente para la prevención o el tratamiento de infecciones virales por dengue. La invención también se refiere a procesos para la preparación de los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17172247 | 2017-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP19083621A true ECSP19083621A (es) | 2019-11-30 |
Family
ID=58745159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI201983621A ECSP19083621A (es) | 2017-05-22 | 2019-11-22 | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11053196B2 (es) |
| EP (1) | EP3630724B1 (es) |
| JP (1) | JP7179773B2 (es) |
| KR (1) | KR102625991B1 (es) |
| CN (1) | CN110753682B (es) |
| AR (1) | AR111820A1 (es) |
| AU (1) | AU2018274101C1 (es) |
| BR (1) | BR112019024311A2 (es) |
| CA (1) | CA3061026C (es) |
| CL (1) | CL2019003309A1 (es) |
| CO (1) | CO2019013042A2 (es) |
| CR (1) | CR20190531A (es) |
| DK (1) | DK3630724T3 (es) |
| EA (1) | EA039702B1 (es) |
| EC (1) | ECSP19083621A (es) |
| ES (1) | ES2884157T3 (es) |
| HR (1) | HRP20210724T1 (es) |
| HU (1) | HUE054379T2 (es) |
| IL (1) | IL270727B2 (es) |
| LT (1) | LT3630724T (es) |
| MX (1) | MX388870B (es) |
| PE (1) | PE20200342A1 (es) |
| PH (1) | PH12019502577A1 (es) |
| SI (1) | SI3630724T1 (es) |
| TW (1) | TWI771420B (es) |
| UA (1) | UA125970C2 (es) |
| UY (1) | UY37741A (es) |
| WO (1) | WO2018215316A1 (es) |
| ZA (1) | ZA201907713B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| BR112018069601A2 (pt) | 2016-03-31 | 2019-01-29 | Janssen Pharmaceuticals Inc | derivados de indolina substituídos como inibidores da replicação viral da dengue |
| BR112018068676A2 (pt) | 2016-03-31 | 2019-01-15 | Janssen Pharmaceuticals Inc | derivados de indol substituídos como inibidores da replicação viral do dengue |
| BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3630723B1 (en) | 2017-05-22 | 2022-08-24 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| AU2019291488B2 (en) * | 2018-06-19 | 2022-02-24 | Novartis Ag | N-substituted tetrahydrothienopyridine derivatives and uses thereof |
| LT3902803T (lt) | 2018-12-27 | 2023-04-25 | Les Laboratoires Servier | Aza-heterobicikliniai mat2a inhibitoriai ir būdai, skirti panaudoti vėžio gydymui |
| WO2023278564A1 (en) | 2021-07-02 | 2023-01-05 | Mirati Therapeutics, Inc. | Aminopyridine-based mta-cooperative prmt5 inhibitors |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19651000A1 (de) | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
| EP1039911B1 (en) | 1997-10-27 | 2005-05-25 | Eli Lilly And Company | MORPHOLINO-N-ETHYL ESTER PRODRUGS OF INDOLE sPLA 2 INHIBITORS |
| US6861504B2 (en) | 2001-05-03 | 2005-03-01 | Cbr, Inc. | Compounds and methods for the modulation of CD154 |
| GB0110832D0 (en) | 2001-05-03 | 2001-06-27 | Virogen Ltd | Antiviral compounds |
| AU2002364566B2 (en) | 2001-12-12 | 2009-03-26 | Conforma Therapeutics Corporation | Assays and implements for determining and modulating HSP90 binding activity |
| GB0215293D0 (en) | 2002-07-03 | 2002-08-14 | Rega Foundation | Viral inhibitors |
| CN101103026A (zh) | 2005-01-14 | 2008-01-09 | 健亚生物科技公司 | 用于治疗病毒感染的吲哚衍生物 |
| KR20070102741A (ko) | 2005-02-09 | 2007-10-19 | 미게닉스 인코포레이티드 | 플라비비리대 감염증을 치료하거나 예방하기 위한 조성물및 방법 |
| AP2010005480A0 (en) | 2008-06-03 | 2010-12-31 | Siga Technologies Inc | Small molecule inhibitors for the treatment or prevention of denque virus infection. |
| US8143259B2 (en) | 2008-08-19 | 2012-03-27 | Janssen Pharmaceutica, Nv | Cold menthol receptor antagonists |
| WO2010021378A1 (ja) | 2008-08-22 | 2010-02-25 | 日本化薬株式会社 | 色素増感型光電変換素子 |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| EP2393359A4 (en) | 2009-02-09 | 2012-10-03 | Enanta Pharm Inc | COMPOUND DIBENZIMIDAZOLE DERIVATIVES |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| US8993604B2 (en) | 2009-06-30 | 2015-03-31 | Siga Technologies, Inc. | Treatment and prevention of dengue virus infections |
| US7948798B1 (en) | 2009-07-22 | 2011-05-24 | Marvell International Ltd. | Mixed multi-level cell and single level cell storage device |
| US8524764B2 (en) | 2010-01-15 | 2013-09-03 | Gilead Sciences, Inc. | Inhibitors of Flaviviridae viruses |
| JP2013523657A (ja) | 2010-03-26 | 2013-06-17 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのインダゾリル‐ピリミジン |
| JP5716205B2 (ja) | 2011-03-29 | 2015-05-13 | 学校法人日本大学 | グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法 |
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB201305376D0 (en) * | 2013-03-25 | 2013-05-08 | Univ Leuven Kath | Novel viral replication inhibitors |
| CA2923712C (en) | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| SG10201908467RA (en) | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| MX2017004298A (es) | 2014-10-01 | 2017-07-19 | Janssen Pharmaceuticals Inc | Indoles mono o disustituidos como inhibidores de la replicacion del virus del denge. |
| ME03360B (me) | 2014-10-01 | 2019-10-20 | Janssen Pharmaceuticals Inc | Mono- ili di-supsтituisani derivaтi indola као inhibiтori replikacije virusa denge |
| NO2721243T3 (es) | 2014-10-01 | 2018-10-20 | ||
| PH12017501272B1 (en) | 2015-01-16 | 2023-01-11 | Janssen Pharmaceuticals Inc | Indole derivatives as dengue viral replication inhibitors |
| AR103680A1 (es) | 2015-02-23 | 2017-05-24 | Lilly Co Eli | Inhibidores selectivos de bace1 |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| RU2761212C2 (ru) | 2015-11-03 | 2021-12-06 | Зоэтис Сервисиз Ллс | Полимерные композиты, полученные по способу золь-гель, и их применение |
| BR112018068676A2 (pt) | 2016-03-31 | 2019-01-15 | Janssen Pharmaceuticals Inc | derivados de indol substituídos como inibidores da replicação viral do dengue |
| EA036637B1 (ru) | 2016-03-31 | 2020-12-02 | Такеда Фармасьютикал Компани Лимитед | Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу |
| BR112018069601A2 (pt) | 2016-03-31 | 2019-01-29 | Janssen Pharmaceuticals Inc | derivados de indolina substituídos como inibidores da replicação viral da dengue |
| ES2891578T3 (es) | 2016-04-01 | 2022-01-28 | Kite Pharma Inc | Antígeno quimérico y receptores de células T y métodos de uso |
| JOP20170069B1 (ar) * | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| CA3019650C (en) | 2016-04-01 | 2023-07-25 | Kite Pharma, Inc. | Chimeric receptors and methods of use thereof |
| MX379513B (es) | 2016-04-01 | 2025-03-11 | Signal Pharm Llc | Compuestos de aminopurina sustituida, composiciones de estos y métodos de tratamiento con estos. |
| BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
| AU2017242539B2 (en) | 2016-04-01 | 2020-10-15 | Basf Se | Bicyclic compounds |
| IL262061B2 (en) | 2016-04-01 | 2023-03-01 | Amgen Inc | Chimeric flt-3 receptors and methods of using them |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| EP3630723B1 (en) | 2017-05-22 | 2022-08-24 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
-
2018
- 2018-05-18 UA UAA201912061A patent/UA125970C2/uk unknown
- 2018-05-18 JP JP2019564452A patent/JP7179773B2/ja active Active
- 2018-05-18 DK DK18729051.5T patent/DK3630724T3/da active
- 2018-05-18 CA CA3061026A patent/CA3061026C/en active Active
- 2018-05-18 SI SI201830306T patent/SI3630724T1/sl unknown
- 2018-05-18 AU AU2018274101A patent/AU2018274101C1/en active Active
- 2018-05-18 ES ES18729051T patent/ES2884157T3/es active Active
- 2018-05-18 HU HUE18729051A patent/HUE054379T2/hu unknown
- 2018-05-18 WO PCT/EP2018/063029 patent/WO2018215316A1/en not_active Ceased
- 2018-05-18 PE PE2019002416A patent/PE20200342A1/es unknown
- 2018-05-18 US US16/614,715 patent/US11053196B2/en active Active
- 2018-05-18 EA EA201992784A patent/EA039702B1/ru unknown
- 2018-05-18 EP EP18729051.5A patent/EP3630724B1/en active Active
- 2018-05-18 MX MX2019013878A patent/MX388870B/es unknown
- 2018-05-18 TW TW107116922A patent/TWI771420B/zh not_active IP Right Cessation
- 2018-05-18 LT LTEP18729051.5T patent/LT3630724T/lt unknown
- 2018-05-18 KR KR1020197037345A patent/KR102625991B1/ko active Active
- 2018-05-18 BR BR112019024311-9A patent/BR112019024311A2/pt not_active Application Discontinuation
- 2018-05-18 IL IL270727A patent/IL270727B2/en unknown
- 2018-05-18 CR CR20190531A patent/CR20190531A/es unknown
- 2018-05-18 HR HRP20210724TT patent/HRP20210724T1/hr unknown
- 2018-05-18 CN CN201880033731.2A patent/CN110753682B/zh active Active
- 2018-05-22 AR ARP180101352A patent/AR111820A1/es not_active Application Discontinuation
- 2018-05-22 UY UY0001037741A patent/UY37741A/es unknown
-
2019
- 2019-11-18 CL CL2019003309A patent/CL2019003309A1/es unknown
- 2019-11-18 PH PH12019502577A patent/PH12019502577A1/en unknown
- 2019-11-21 ZA ZA2019/07713A patent/ZA201907713B/en unknown
- 2019-11-22 CO CONC2019/0013042A patent/CO2019013042A2/es unknown
- 2019-11-22 EC ECSENADI201983621A patent/ECSP19083621A/es unknown
-
2021
- 2021-05-28 US US17/334,432 patent/US11702387B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19070413A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073245A (es) | Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue | |
| NI201700137A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicaciãn viral del dengue | |
| CL2018002784A1 (es) | Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue. | |
| MX2018003256A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicacion viral del dengue. | |
| CL2017001822A1 (es) | Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue |